BiomEnforcer®: Empirical In Vivo Validation of Filamentous Protein Matrix (Patent UA 141234) — Version 2.0

Can biological systems overcome severe nutritional starvation and metabolic collapse without increasing dietary protein loads? This technical validation report presents compelling in vivo evidence demonstrating how pre-emptive structural restructuring of native globular proteins into open-chain filamentous conformations provides an immediate thermodynamic shunt for living systems under extreme alimentary deprivation and toxic stress. Key Empirical Findings Substrate & Technology: BiomEnforcer® (Patent of Ukraine for Utility Model No. 141234) — a bioactive complex combining mechanically uncoiled protein filaments with a functional Saccharomyces spp. matrix carrier. Stress Model: Commercial laying hens (n=150) subjected to acute dietary protein deficits (11.43% CP; 23–28% below breed standard), high feed titratable acidity (7.1°), and chronic background mycotoxin exposure across three age cohorts (28.5–30, 83–85, and 150–175 weeks). Micro-Dose Efficiency: Administered at a micro-inclusion rate of just 0.1% (1.0 kg/t of compound feed). Somatic Restoration: Reversed systemic wasting, driving somatic body mass gains of +14.0% to +14.56% in aged and metabolically exhausted flocks. Reproductive Reactivation: Following a 21-day metabolic reprogramming phase, oviposition surged across all cohorts, reaching peak laying rates of 80–100% (averaging 40.5% in geriatric birds aged 150–175 weeks). Histomorphological Confirmation: Active osteomedullary calcium mobilization and transient hepatic lipid turnover confirmed deep systemic reactivation without placing energetic strain on endogenous digestive enzyme systems. Theoretical Significance: By eliminating steric barriers and minimizing the thermodynamic activation energy required for enzymatic cleavage, filamentous protein matrices act as direct bio-regulative donors of plastic and energetic substrates, bypassing classical digestive bottlenecks. Supplementary Linkage: This publication provides empirical proof-of-concept and in vivo validation data directly supplementary to the foundational Zenodo deposit: https://doi.org/10.5281/zenodo.20377526 Corporate R&D & Scientific Framework: Detailed scientific documentation, architectural principles, and advanced biotechnology developments are available at: https://pmtstructure.com/